SYSA-1801 is under clinical development by Elevation Oncology and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase I drugs for Metastatic Pancreatic Cancer have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SYSA-1801’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SYSA-1801 overview

SYSA-1801 is under development for the treatment of metastatic gastric cancer, gastroesophageal junction adenocarcinoma, non-small cell lung cancer, esophageal cancer and pancreatic cancer. The drug candidate comprises of fully human anti-claudin-18.2 monoclonal antibody is conjugated with monomethyl auristatin E (MMAE). It is administered through intravenous drip route.

Elevation Oncology overview

Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients. Elevation Oncology is headquartered in New York City, New York, the US.

For a complete picture of SYSA-1801’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.